Caffeine, a Risk Factor for Osteoarthritis and Longitudinal Bone Growth Inhibition

Osteoarthritis (OA), the most common chronic rheumatic disease, is mainly characterized by a progressive degradation of the hyaline articular cartilage, which is essential for correct joint function, lubrication, and resistance. Articular cartilage disturbances lead to joint failure, pain, and disability. Hyaline cartilage is also present in the growth plate and plays a key role in longitudinal bone growth. Alterations of this cartilage by diverse pathologies have been related to longitudinal bone growth inhibition (LBGI), which leads to growth retardation. Diet can play a crucial role in processes involved in the OA and LBGI's onset and evolution. Specifically, there is ample evidence pointing to the negative impacts of caffeine consumption on hyaline cartilage. However, its effects on these tissues have not been reviewed. Accordingly, in this review, we summarize all current knowledge in the PubMed database about caffeine catabolic effects on articular and growth plate cartilage. Specifically, we focus on the correlation between OA and LBGI with caffeine prenatal or direct exposure. Overall, there is ample evidence indicating that caffeine intake negatively affects the physiology of both articular and growth plate cartilage, increasing consumers predisposition to suffer OA and LBGI. As a result, caffeine consumption should be avoided for these pathologies

Programa Gallego de Atenci?n al Infarto Agudo de Miocardio. Protocolo de actuaci?n para pacientes con s?ndrome coronario agudo con elevaci?n del segmento ST en Galicia

A enfermidade coronaria sup?n un importante problema de sa?de p?blica debido ? s?a incidencia crecente e a que constit?e a principal causa de morte no mundo. no ?mbito da Comunidade Aut?noma de Galicia, p?xose en marcha en maio de 2005 o Programa Galego de Atenci?n ao Infarto Agudo de Miocardio (PROGALIAM). Este programa foi un dos primeiros en implantarse en Espa?a (s? por detr?s dos de Murcia e Navarra). Debido ao tempo transcorrido, viuse necesario adaptar o Progaliam do ano 2005 ?s novas e actuais evidencias, e ?s actuais recomendaci?ns das Gu?as de Pr?ctica Cl?nica. ? por iso, que na Direcci?n Xeral de Asistencia Sanitaria, constitu?use un grupo de traballo formado por cardi?logos intervencionistas das 7 ?reas sanitarias, as? como profesionais m?dicos de Atenci?n Primaria e Urxencias.La enfermedad coronaria supone un importante problema de salud p?blica debido a su incidente creciente y la que constituye la principal causa de muerte en el mundo. en el ?mbito de la Comunidad Aut?noma de Galicia, se puso en marcha en mayo de 2005 el Programa Gallego de Atenci?n al Infarto Agudo de Miocardio (PROGALIAM). Este programa fue uno de los primeros en implantarse en Espa?a (solo por detr?s de los de Murcia y Navarra). Debido al tiempo transcurrido, se vio necesario adaptar el Progaliam del a?o 2005 a las noticias y actuales evidencias, y a las actuales recomendaciones de las Gu?as de Pr?ctica Cl?nica. Es por eso, que en la Direcci?n General de Asistencia Sanitaria, se constituy? un grupo de trabajo formado por cardi?logos intervencionistas de las 7 ?reas sanitarias, as? como profesionales m?dicos de Atenci?n Primaria y Urgencias

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.

Funder: laura and john arnold foundationBACKGROUND: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). METHODS: In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung-Knapp-Sidik-Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. RESULTS: A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. CONCLUSIONS: Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care

Programa gallego de atenci?n al infarto agudo de miocardio. Protocolo de actuaci?n para pacientes con s?ndrome coronario agudo con elevaci?n del segmento ST en Galicia. Gu?a r?pida visual

Nesta gu?a presentase o Protocolo de actuaci?n para pacientes con s?ndrome coronaria aguda con elevaci?n del segmento ST en Galicia. Consta do algoritmo de reperfusi?n, da terapia inicial, as? como dos circuitos e tempos indicados para abordar esta patolox?a.En esta gu?a se presenta el Protocolo de actuaci?n para pacientes con s?ndrome coronario agudo con elevaci?n del segmento ST en Galicia. Consta del algoritmo de reperfusi?n, de la terapia inicial, as? como de los circuitos y tiempos indicados para abordar esta patolog?a

Retiro temprano de esteroides en una cohorte de trasplante renal tratada con tacrolimus, mofetil micofenolato y basiliximab

Antecedentes: No hay suficiente evidencia sobre la frecuencia de rechazo agudo y la funci�n del injerto en los pacientes con retiro temprano de esteroides (RTE). El objetivo del presente estudio es comparar el efecto del RTE sobre la tasa de filtrado glomerular (TFG), la supervivencia/rechazo del injerto en receptores de una cohorte de tratados con tacrolimus/mofetil micofenolato, comparada con un grupo control. Material y m�todos: Cohorte retrospectiva en 60 receptores de bajo riesgo inmunol�gico entre diciembre de 2005 y julio de 2010. Cohorte del estudio (C-RTE; N = 32), el RTE se hizo el 5� d�a mientras recib�an tacrolimus/mofetil micofenolato. La cohorte control (C-C, N = 28) recibi� prednisona/tacrolimus/mofetil micofenolato. Las variables cl�nicas, bioqu�micas e histol�gicas fueron evaluadas al inicio del estudio, y a los 3, 6 y 12 meses de seguimiento. Se utiliz� Kaplan-Meier y el modelo de riesgos proporcionales de Cox para evaluar la supervivencia. Las comparaciones entre cohortes fueron hechas por la t de Student y ?�. Resultados: Durante el seguimiento, la C-C muestra presi�n sangu�nea significativamente mayor tanto sist�lica (125 � 10 frente a 114 � 8) como diast�lica (81 � 8 frente a 72 � 7), glucosa s�rica (96 � 13 frente a 86 � 10), triglic�ridos (177 � 61 frente a 129 � 34), colesterol total (183 � 43 frente a 148 � 34) y colesterol LDL (100 � 22 frente a 87 � 25). La C-C present� una mayor proporci�n de uso de antihipertensivos (57 frente a 13 %) y de estatinas (27 frente a 9 %). La TFGe fue mejor en la C-RTE que en la C-C (85,4 � 20,6 frente a 70,6 � 17,0, p = 0,004). La frecuencia de rechazo agudo fue menor en la C-RTE. Conclusiones: La supervivencia del injerto, la TFG, la tasa de rechazo agudo y el perfil metab�lico fueron mejores en la C-RTE que en la C-C